Skip to contentA
aTYR PHARMA INC
A
ATYRaTYR PHARMA INC Q3 2023 · 10-Q
Revenue$353.00K$353.00K— vs Q3 2022 Net Income-$11.34M-$11.34MN/M vs Q3 2022 EPS Diluted-$0.20-$0.20N/M vs Q3 2022 Operating Income-$12,615,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
aTYR PHARMA INC · CIK 1339970 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$10,116,000N/M Margins · derivedOperating margin-3573.7%
Net margin-3212.5%
ended Sep 30, 2023 · filed Nov 9, 2023 · 40 d after period end